Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy-Reference-Cited by-同舟云学术

Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy

Published:2019-09 Issue:5 Volume:2 Page:565-571
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Patterson Karl,Prabhu Vimalanand,Xu Ruifeng,Li Haojie,Meng Yang,Zarabi Natalie,Zhong Yichen,Batteson Rachael,Pellissier James,Keefe Stephen,Grivas Petros,de Wit Ronald

Publisher

Elsevier BV

Subject

Urology,Radiology Nuclear Medicine and imaging,Oncology,Surgery

Reference30 articles.

1. Regionala Cancercentrum i sSmverkan. Cancer i urinblåsa, njurbäcken, urin-ledare och urinrör Nationellt vårdprogram. www.cancercentrum.se/globalassets/cancerdiagnoser/urinvagar/urinblase--och-urinrorscancer/vardprogram/natvp_cancer_urinvagar_25aug15.pdf

2. Regionala Cancercentrum i Samverkan. Nationellt kvalitetsregister för urinblåsecancer Kvalitetsregisterrapport, diagnosår 2015. https://www.cancercentrum.se/globalassets/cancerdiagnoser/urinvagar/urinblase--och-urinrorscancer/rapport.2015final.pdf

3. Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer;Sonpavde;Clin Genitourin Cancer,2014

4. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community;Sonpavde;Clin Genitourin Cancer,2012

5. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances of Neoadjuvant Immunotherapy for Urothelial Bladder Cancer;Annals of Surgical Oncology;2024-07-12

2. Cost-Effectiveness of Treatment Optimisation with Biomarkers for Immunotherapy in Solid Tumours: A Systematic Review;Cancers;2024-02-29

3. A cost‐effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first‐line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan;Cancer Reports;2023-08-28

4. The Evolving Role of Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma: A Literature Review of Practice-Changing Trials;Journal of Urologic Oncology;2023-07-31

5. Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+);Cancers;2022-10-27